{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:03:59Z","timestamp":1765357439007,"version":"3.41.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Rheumatoid arthritis (RA) affects about 1% of the world's population and can lead to loss of joint function, reduced mobility, and permanent damage to cartilage and bone. Treatment options for RA primarily include disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, but the development of new drugs has complicated treatment decisions. Weighing treatment options for patients with RA largely depends on three major factors: efficacy, adverse reaction profile, and cost. A review of the literature supports methotrexate monotherapy as the current best-practice model for treating RA, compared with combination therapy of methotrexate and\/or other DMARDs.<\/jats:p>","DOI":"10.1097\/01.jaa.0000937316.70181.ff","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T14:02:07Z","timestamp":1693922527000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Treating rheumatoid arthritis"],"prefix":"10.1097","volume":"36","author":[{"given":"Ihor","family":"Korol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin H.","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"2","key":"R1-20250605","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/14397595.2018.1546357","article-title":"IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review","volume":"29","author":"Ogata","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"4","key":"R2-20250605","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.pop.2010.07.001","article-title":"Emerging trends in diagnosis and treatment of rheumatoid arthritis","volume":"37","author":"Birch","year":"2010","journal-title":"Prim Care"},{"issue":"13","key":"R3-20250605","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"R4-20250605","first-page":"36","article-title":"Rheumatoid arthritis diagnosis and management","volume":"44","author":"Ryan","year":"2014","journal-title":"Practice Nurse"},{"issue":"1","key":"R5-20250605","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1185\/03007990903422307","article-title":"Societal cost of rheumatoid arthritis patients in the US","volume":"26","author":"Birnbaum","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"10086","key":"R6-20250605","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"R7-20250605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"R8-20250605","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"R9-20250605","first-page":"CD010227","article-title":"Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis","volume":"2016","author":"Hazlewood","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"R10-20250605","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.38323","article-title":"Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis","volume":"66","author":"Solomon","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"R11-20250605","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1759720X16665330","article-title":"Combination therapy with biologic agents in rheumatic diseases: current and future prospects","volume":"8","author":"Inui","year":"2016","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"R12-20250605","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1759720X11408635","article-title":"Methotrexate: optimizing the efficacy in rheumatoid arthritis","volume":"3","author":"Braun","year":"2011","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"R13-20250605","doi-asserted-by":"crossref","first-page":"e000993","DOI":"10.1136\/rmdopen-2019-000993","article-title":"Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift","volume":"5","author":"Chatzidionysiou","year":"2019","journal-title":"RMD Open"},{"key":"R14-20250605","first-page":"16","article-title":"Methotrexate in rheumatoid arthritis: a quarter century of development","volume":"124","author":"Weinblatt","year":"2013","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"5","key":"R15-20250605","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jbspin.2016.10.010","article-title":"Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: meta-analysis of randomized controlled trials","volume":"84","author":"Mazouy\u00e8s","year":"2017","journal-title":"Joint Bone Spine"},{"issue":"4","key":"R16-20250605","first-page":"CD008495","article-title":"Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis","volume":"2010","author":"Katchamart","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"10093","key":"R17-20250605","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"R18-20250605","first-page":"1","article-title":"Efficacy of sulphasalazine plus methotrexate in rheumatoid arthritis","volume":"26","author":"Islam","year":"2000","journal-title":"Bangladesh Med Res Counc Bull"},{"issue":"5","key":"R19-20250605","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/art.21796","article-title":"Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study","volume":"54","author":"Hetland","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2147\/PPA.S165101","article-title":"Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review","volume":"12","author":"Anghel","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"R21-20250605","first-page":"CD000951","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"2013","author":"Shea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"R22-20250605","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7609.1000125","article-title":"Methotrexate side effects: review article","volume":"3","author":"Gaies","year":"2012","journal-title":"J Drug Metab Toxicol"},{"issue":"7","key":"R23-20250605","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s10067-019-04577-3","article-title":"Reversible alopecia areata: a little known side effect of leflunomide","volume":"38","author":"Koller","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"3","key":"R24-20250605","doi-asserted-by":"crossref","first-page":"377","DOI":"10.7326\/0003-4819-101-3-377","article-title":"Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development","volume":"101","author":"Peppercorn","year":"1984","journal-title":"Ann Intern Med"},{"article-title":"Disease modifying anti-rheumatic drugs (DMARDs)","year":"2020","author":"Benjamin","key":"R25-20250605"},{"issue":"7","key":"R26-20250605","first-page":"1051","article-title":"The impact of socio-economic status in rheumatoid arthritis","volume":"56","author":"Verstappen","year":"2017","journal-title":"Rheumatology"},{"issue":"5","key":"R27-20250605","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003495-200565050-00006","article-title":"Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis","volume":"65","author":"Nurmohamed","year":"2005","journal-title":"Drugs"},{"issue":"10","key":"R28-20250605","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.23512","article-title":"Medical care costs associated with rheumatoid arthritis in the US: a systematic literature review and meta-analysis","volume":"70","author":"Hresko","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"R29-20250605","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/M16-0713","article-title":"Triple therapy versus biologic therapy for active rheumatoid arthritis: a cost-effectiveness analysis","volume":"167","author":"Bansback","year":"2017","journal-title":"Ann Intern Med"},{"issue":"6","key":"R30-20250605","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/art.39079","article-title":"Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D","volume":"67","author":"Yazdany","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"R31-20250605","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11926-020-00921-8","article-title":"Therapeutic options and cost-effectiveness for rheumatoid arthritis treatment","volume":"22","author":"Drosos","year":"2020","journal-title":"Curr Rheumatol Rep"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000937316.70181.ff","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:03:15Z","timestamp":1749153795000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000937316.70181.ff"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000937316.70181.ff","relation":{},"ISSN":["1547-1896"],"issn-type":[{"type":"print","value":"1547-1896"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}